Study #2021-0750
An open-label, multi-center, Phase I study of oral IAG933 in adult patients with advanced Mesothelioma and other solid tumors
MD Anderson Study Status
Enrolling
Treatment Agent
IAG933
Description
The purpose of this study is to characterize the safety and tolerability of IAG933 in patients with mesothelioma, NF2/LATS1/LATS2 mutated tumors and tumors with functional YAP/TAZ fusions and to identify the maximum tolerated dose and/or recommended dose.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Mesothelioma
Study phase:
Phase I
Physician name:
Mehmet Altan
Department:
Thoracic/Head & Neck Medical Oncology
For general questions about clinical trials:
1-855-900-1058
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.